Nvelop Therapeutics, a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, has officially announced to develop the next generation of genetic medicines for a wide range of diseases.

The company’s approach has the potential to enable highly efficient and cell-specific delivery of a broad set of therapeutic cargoes.

“The field of genetic medicine is significantly limited by the challenge of efficiently delivering therapeutic cargoes to many types of target cells in vivo,” said Jeff Walsh, Nvelop’s Chief Executive Officer.

“With the combination of best-in-class technologies, scientific co-founders with a deep track record in cell and gene therapy, and a team that has pioneered the development of some of the first approved therapies in the field, Nvelop is uniquely positioned to unlock the promise of genetic medicines,” added Walsh.

Nvelop’s modular platforms are based on two in vivo validated delivery approaches developed at the Broad Institute of MIT and Harvard, and Massachusetts General Hospital by luminaries in the gene editing field Co-Founders David Liu, PhD, and Keith Joung, MD, PhD. One of Nvelop’s platform technologies, with in vivo data, has been published in prestigious peer-reviewed journals, including Cell (2022) and Nature Biotechnology (2024). In vivo data for the second platform is expected to be disclosed at one or more scientific meetings this year.

“At Nvelop, we stand on the cusp of an extraordinary journey, as our delivery technologies have the potential to be truly disruptive,” said Melissa Bonner, PhD, Nvelop’s Chief Scientific Officer.

“I’m excited to be a part of a team committed to building a future in which curative therapies are more broadly accessible,” stated Bonner.

In addition to its distinguished scientific co-founders, Nvelop has assembled a team of experienced scientists, industry executives, and company builders with a collective reputation for innovation and business excellence. Nvelop was founded in 2022, having raised an initial round of USD 100 million.

“At Nvelop, we’re building a culture of curiosity, trust and mutual respect, where we are invested in each employee’s growth because we believe that great science that brings benefit to patients is only possible in an environment that fosters the best in everyone,” added Walsh.